Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1949 1
1950 2
1954 4
1955 4
1956 4
1957 3
1958 2
1959 1
1961 2
1962 3
1963 2
1964 4
1965 1
1966 1
1967 3
1968 3
1969 1
1970 3
1971 2
1972 2
1973 9
1974 12
1975 9
1976 4
1977 10
1978 7
1979 7
1980 7
1981 1
1982 5
1983 9
1984 14
1985 11
1986 11
1987 20
1988 35
1989 51
1990 41
1991 61
1992 62
1993 62
1994 63
1995 71
1996 94
1997 87
1998 90
1999 101
2000 98
2001 95
2002 90
2003 85
2004 109
2005 123
2006 101
2007 115
2008 104
2009 73
2010 78
2011 121
2012 108
2013 93
2014 108
2015 114
2016 119
2017 106
2018 104
2019 102
2020 110
2021 99
2022 108
2023 97
2024 109
2025 112
2026 58

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,465 results

Results by year

Filters applied: . Clear all
Page 1
Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.
Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Tabuteau H, et al. Am J Psychiatry. 2022 Jul;179(7):490-499. doi: 10.1176/appi.ajp.21080800. Epub 2022 May 18. Am J Psychiatry. 2022. PMID: 35582785 Clinical Trial.
Most secondary outcomes favored dextromethorphan-bupropion. The most common adverse events with dextromethorphan-bupropion were dizziness, nausea, dry mouth, decreased appetite, and anxiety. Dextromethorphan-bupropion was not associated with psychotomimetic e …
Most secondary outcomes favored dextromethorphan-bupropion. The most common adverse events with dextromethorphan-bupropion wer …
Dextromethorphan/Bupropion: First Approval.
Keam SJ. Keam SJ. CNS Drugs. 2022 Nov;36(11):1229-1238. doi: 10.1007/s40263-022-00968-4. CNS Drugs. 2022. PMID: 36301443 Review.
An oral, fixed-dose combination of dextromethorphan hydrobromide [an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist] and the antidepressant bupropion hydrochloride (an aminoketone and CYP2D6 inhibitor that increases dextrometh …
An oral, fixed-dose combination of dextromethorphan hydrobromide [an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist an …
Drugs for cough.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2018 Dec 17;60(1562):206-208. Med Lett Drugs Ther. 2018. PMID: 30625123 Review. No abstract available.
Dextromethorphan abuse.
Boyer EW. Boyer EW. Pediatr Emerg Care. 2004 Dec;20(12):858-63. doi: 10.1097/01.pec.0000148039.14588.d0. Pediatr Emerg Care. 2004. PMID: 15572980 Review.
Dextromethorphan is an over-the-counter dissociative agent of increasing popularity as a drug of abuse among younger adolescents. ...Most cases improve with supportive care alone, but severely intoxicated patients may require significant attention. Because dextromethorp …
Dextromethorphan is an over-the-counter dissociative agent of increasing popularity as a drug of abuse among younger adolescents. ... …
New Combination Drug for Depression.
Aschenbrenner DS. Aschenbrenner DS. Am J Nurs. 2023 Apr 1;123(4):24-25. doi: 10.1097/01.NAJ.0000925488.72453.63. Am J Nurs. 2023. PMID: 36951340
Auvelity, an extended-release fixed combination of dextromethorphan and bupropion, is approved for the treatment of major depressive disorder in adults.Like all antidepressants, dextromethorphan-bupropion carries a boxed warning that it may increase the risk of suic …
Auvelity, an extended-release fixed combination of dextromethorphan and bupropion, is approved for the treatment of major depressive …
Dextromethorphan.
Banken JA, Foster H. Banken JA, et al. Ann N Y Acad Sci. 2008 Oct;1139:402-11. doi: 10.1196/annals.1432.003. Ann N Y Acad Sci. 2008. PMID: 18991887
Dextromethorphan is reviewed in its role as an emerging drug of abuse, and the effects of dextromethorphan, along with those of co-ingredients in OTC formulations, are discussed. The Drug Abuse and Warning Network (DAWN) national data in the United States are examin …
Dextromethorphan is reviewed in its role as an emerging drug of abuse, and the effects of dextromethorphan, along with those o …
Classics in Chemical Neuroscience: Dextromethorphan (DXM).
McClure EW, Daniels RN. McClure EW, et al. ACS Chem Neurosci. 2023 Jun 21;14(12):2256-2270. doi: 10.1021/acschemneuro.3c00088. Epub 2023 Jun 8. ACS Chem Neurosci. 2023. PMID: 37290117 Review.
Dextromethorphan (DXM) was introduced in 1958 as the first non-opioid cough suppressant and is indicated for multiple psychiatric disorders. ...
Dextromethorphan (DXM) was introduced in 1958 as the first non-opioid cough suppressant and is indicated for multiple psychiatric dis …
Contrave, Lybalvi, Auvelity, and Cobenfy: What Do They Have in Common?
Preskorn SH. Preskorn SH. J Psychiatr Pract. 2025 Jul 1;31(4):214-216. doi: 10.1097/PRA.0000000000000863. J Psychiatr Pract. 2025. PMID: 40679802 Review.
This column reviews 4 psychiatric combination products: Contrave (bupropion + naltrexone), Lybalvi (olanzapine + samidorphan), Auvelity (dextromethorphan + bupropion), and Cobenfy (xanomeline + trospium). All have been approved in the last 11 years. ...
This column reviews 4 psychiatric combination products: Contrave (bupropion + naltrexone), Lybalvi (olanzapine + samidorphan), Auvelity ( …
Dextromethorphan.
Löscher W, Netzer R, Schmitt B. Löscher W, et al. Neurology. 1994 Mar;44(3 Pt 1):582-3. doi: 10.1212/wnl.44.3_part_1.582-b. Neurology. 1994. PMID: 8179707 No abstract available.
3,465 results